Equity Overview
Price & Market Data
Price: $13.67
Daily Change: -$0.52 / 3.80%
Daily Range: $13.49 - $14.54
Market Cap: $511,811,648
Daily Volume: 99,043
Performance Metrics
1 Week: 0.59%
1 Month: -3.94%
3 Months: 43.29%
6 Months: -4.34%
1 Year: -26.96%
YTD: -29.50%
Company Details
Employees: 28
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.